The Japanese Red Cross Medical Center is a hospital located in Hiroo, Shibuya-ku, Tokyo. It is the central medical center of the Japanese Red Cross Society, and is directly controlled by it. The site of Hiroo, Tokyo, where the medical center is currently located, was where a mansion of Horita Binakamori once stood.

During the past decade, Japanese Red Cross Medical Center conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 17 clinical trials were completed, i.e. on average, 43.6% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 11 clinical trials were completed. i.e. 61.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Japanese Red Cross Medical Center" #1 sponsor was "Janssen Research & Development, LLC" with 9 trials, followed by "Pfizer" with 9 trials sponsored, "Celgene" with 8 trials sponsored, "Takeda" with 4 trials sponsored and "Amgen" with 4 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Japanese Red Cross Medical Center" #1 collaborator was "Tokyo Medical and Dental University" with 2 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Japan Blood Products Organization" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Japanese Red Cross Medical Center" are "Multiple Myeloma" (20 trials), "Colorectal Cancer" (2 trials), "Low Back Pain" (2 trials), "Myelodysplastic Syndrome" (2 trials) and "Myelodysplastic Syndromes" (2 trials). Many other conditions were trialed in "Japanese Red Cross Medical Center" in a lesser frequency.

Most popular intervention types in "Japanese Red Cross Medical Center" are "Drug" (41 trials), "Biological" (5 trials), "Procedure" (2 trials), "Device" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Dexamethasone" (12 trials), "Bortezomib" (9 trials), "Lenalidomide" (8 trials), "Daratumumab" (7 trials) and "Carfilzomib" (5 trials). Other intervention names were less common.

The vast majority of trials in "Japanese Red Cross Medical Center" are 48 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Japanese Red Cross Medical Center". undefined are not yet recruiting, 12 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Japanese Red Cross Medical Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Japanese Red Cross Medical Center, 8 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".